Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Lekka,Dr Vadratsikas

Our institutional guidelines discussed Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

The first successful trial in steroid refractory GVHD. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

We discussed a case of CNS lymphoma and the diffrent HD regimens. we favour regimens with Rituxmab, Thiotepa and bu or AraC   R-Busulfan-thiotepa Rituximab -6 Busulfan 2 days -5, -4 Thiotepa 5 mg/kg days -4 and -3   (https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-5473-z)   Other regimens Regimen without Thiotepa BUCYE Busulfan 3.2 mg/kg days...

We discussed the current EBMT guidelines for COVID19. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

The current Indications for HCT were discussed. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

This cohort analysis evaluates theincidence, risk factors and mortality of pre-engraftment blood-stream infections(BSIs) and ds-DNAviral infections (VIs) after HSCTwith post-transplant cyclophosphamide(PT-Cy) platform among different donor sourcesAllogeneic HSCT with PT-Cy showed a 32% incidence of pre-engraftment BSIsand donor type did not affect their occurrence·VIsare common in early...

Even at low doses, nivolumab maintenance after allo-SCT can cause serious immune-related toxicitiesWe report rapid, unexpected occurrences of grade 3/4 immune-related adverse events ·Nivolumab enhanced the graft-vs-tumor response but more studies are needed to improve tolerability Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

An excellent overview. We discusssed the differences betwen current used flt3 inhibitors. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

An article published in BMT suggest that PT/Cy-haplo recipients may  reconstitute CMV-specific T-cell immunity to the same extent as patients  undergoing HLA-matched allo-HSCT Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas

Results of the international MRC UKALLXII/ECOG E2993 trial. Out of the  1 752 patients who achieved CR, 11·7% underwent autologous and 40·6%  allogeneic transplant, while in CR1. Of the autologous patients, 43·2%  relapsed early and 3·4% relapsed late. However, among the allogeneic  patients, 13·2% relapsed early and only 1·3%...

Excellent review. The most of the newly approved drugs are for pts >75  years. The "problems"  of the approval trials are discussed. AS the  authro points: Don’t trust the horse, Trojans. Whatever it is, I fearthe Greeks even  bearing gifts.)—Virgi Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou,...

A combination of phenotypic and functional immune assays enables risk-stratification of patients with viral infections after transplantFunctional immune monitoring can help identify patients in need of additional antiviral intervention Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Fragopanagou, Dr Vadratsikas